| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
Inveltys is owned by Alcon Labs Inc.
Inveltys contains Loteprednol Etabonate.
Inveltys has a total of 1 drug patent out of which 0 drug patents have expired.
Inveltys was authorised for market use on 22 August, 2018.
Inveltys is available in suspension/drops;ophthalmic dosage forms.
The generics of Inveltys are possible to be released after 03 May, 2033.
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
INVELTYS family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056057 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9532955 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10058511 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11219597 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10864219 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9737491 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10688045 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10646437 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
Inveltys is owned by Kala Pharms Inc.
Inveltys contains Loteprednol Etabonate.
Inveltys has a total of 10 drug patents out of which 0 drug patents have expired.
Inveltys was authorised for market use on 22 August, 2018.
Inveltys is available in suspension/drops;ophthalmic dosage forms.
Inveltys can be used as a method for delivering a composition to a mucus membrane, a method for delivering a pharmaceutical agent across a mucosal barrier, a method for treating inflammation and/or other disorders in an eye of a patient, a method for treating ocular inflammation, a method of reducing post-surgical pain following ocular surgery; a method of treating postoperative inflammation following ocular surgery.
The generics of Inveltys are possible to be released after 03 May, 2033.
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; A ...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
INVELTYS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic